Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas

References

• Lieber MR. Mechanisms of human lymphoid chromosomal translocations. Nat Rev Cancer. 2016;16(6):387–398.
   PubMed Web of Science ®Google Scholar
• Davoli T, Uno H, Wooten EC, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322):eaaf8399.
   PubMed Web of Science ®Google Scholar
• Robinson WP. Mechanisms leading to uniparental disomy and their clinical consequences. Bioessays News Rev Mol Cell Dev Biol. 2000;22(5):452–459.
   PubMed Web of Science ®Google Scholar
• Struski S, Gervais C, Helias C, et al. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia. 2009;23(3):617–619.
   PubMed Web of Science ®Google Scholar
• Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer. 2009;48(10):843–853.
   PubMed Web of Science ®Google Scholar
• Bishop R. Applications of fluorescence in situ hybridization (FISH) in detecting genetic aberrations of medical significance. Biosci Horiz Int J Stud Res. 2010;3(1):85–95.
   Google Scholar
• Kearney L. Molecular cytogenetics. Best Pract Res Clin Haematol. 2001;14(3):645–669.
   PubMed Web of Science ®Google Scholar
• Kearney L. Multiplex-FISH (M-FISH): technique, developments and applications. Cytogenet Genome Res. 2006;114(3–4):189–198.
   PubMed Web of Science ®Google Scholar
• Shinawi M, Cheung SW. The array CGH and its clinical applications. Drug Discov Today. 2008;13(17–18):760–770.
   PubMed Web of Science ®Google Scholar
• Carter NP. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet. 2007;39(7 Suppl):S16–21.
   PubMed Web of Science ®Google Scholar
• Shaikh TH. Oligonucleotide arrays for high-resolution analysis of copy number alteration in mental retardation/multiple congenital anomalies. Genet Med Off J Am Coll Med Genet. 2007;9(9):617–625.
   Google Scholar
• Scott SA, Cohen N, Brandt T, et al. Detection of low-level mosaicism and placental mosaicism by oligonucleotide array comparative genomic hybridization. Genet Med Off J Am Coll Med Genet. 2010;12(2):85–92.
   Google Scholar
• Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–325.
   PubMed Web of Science ®Google Scholar
• Cui W, Cai Y, Wang W, et al. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. J Transl Med. 2014;12:10.
   PubMed Web of Science ®Google Scholar
• Carey CD, Gusenleitner D, Chapuy B, et al. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn JMD. 2015;17(1):19–30.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M. Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
   PubMed Web of Science ®Google Scholar
• Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009;458(7234):97–101.
   PubMed Web of Science ®Google Scholar
• Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(17):2902–2913.
   PubMed Web of Science ®Google Scholar
• Leroux D, Monteil M, Sotto JJ, et al. Variant t(2;18) translocation in a follicular lymphoma. Br J Haematol. 1990;75(2):290–292.
   PubMed Web of Science ®Google Scholar
• Baseggio L, Geay M-O, Gazzo S, et al. In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. Br J Haematol. 2012;158(4):489–498.
   PubMed Web of Science ®Google Scholar
• Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(13):1347–1355.
   PubMed Web of Science ®Google Scholar
• Horsman DE, Connors JM, Pantzar T, et al. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer. 2001;30(4):375–382.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Al-Tourah A, Brown CJ, et al. Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes Cancer. 2008;47(12):1038–1048.
   PubMed Web of Science ®Google Scholar
• Höglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39(3):195–204.
   PubMed Web of Science ®Google Scholar
• Viardot A, Möller P, Högel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(23):4523–4530.
   PubMed Web of Science ®Google Scholar
• Cheung K-J-J, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113(1):137–148.
   PubMed Web of Science ®Google Scholar
• Schwaenen C, Viardot A, Berger H, et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer. 2009;48(1):39–54.
   PubMed Web of Science ®Google Scholar
• O’Shea D, O’Riain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood. 2009;113(10):2298–2301.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113(5):1053–1061.
   PubMed Web of Science ®Google Scholar
• Louissaint A, Schafernak KT, Geyer JT, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–1100.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Ross CW, Ouillette PD, Saddler CM, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(16):4777–4785.
   PubMed Web of Science ®Google Scholar
• Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood. 2003;102(4):1443–1448.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416–3423.
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121–1127.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Meeus P, Stul M, et al. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia. 2004;18(10):1705–1710.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735–3741.
   PubMed Web of Science ®Google Scholar
• Seto M. Cyclin D1-negative mantle cell lymphoma. Blood. 2013;121(8):1249–1250.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121(8):1394–1402.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111(12):5683–5690.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–1562.
   PubMed Web of Science ®Google Scholar
• Narurkar R, Alkayem M, Liu D. SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma. Biomark Res. 2016;4:6.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Terré C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014;53(1):106–116.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307–5316.
   PubMed Web of Science ®Google Scholar
• Zinzani PL. The many faces of marginal zone lymphoma. Hematol Am Soc Hematol Educ Program. 2012;(2012:426–432.
   PubMedGoogle Scholar
• Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia. 1997;11(5):747–758.
   PubMed Web of Science ®Google Scholar
• Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479–1488.
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93(11):3601–3609.
   PubMed Web of Science ®Google Scholar
• Witkowska M, Smolewski P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm. 2013;2013:1–8.
   Web of Science ®Google Scholar
• Martinez-Climent JA. The origin and targeting of mucosa-associated lymphoid tissue lymphomas. Curr Opin Hematol. 2014;21(4):309–319.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595–1604.
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12):2375–2385.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 2013;98(4):649–654.
   PubMed Web of Science ®Google Scholar
• Monge J, Braggio E, Ansell SM. Genetic factors and pathogenesis of Waldenström’s macroglobulinemia. Curr Oncol Rep. 2013;15(5):450–456.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–1412.
   PubMed Web of Science ®Google Scholar
• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742–751.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Collins R, Shakhan S, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(21):6778–6790.
   PubMed Web of Science ®Google Scholar
• Garg R, Wierda W, Ferrajoli A, et al. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer. 2012;118(14):3531–3537.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Rigolin GM, Bigoni R, et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia. 2004;18(3):476–483.
   PubMed Web of Science ®Google Scholar
• Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–2908.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen H-C, Su X, et al. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J. 2016;6(9):e465.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Li J, Shaknovich R, et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2012;51(12):1125–1132.
   PubMed Web of Science ®Google Scholar
• Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12):2854–2862.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(29):4473–4479.
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(16):2223–2229.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(19):2703–2708.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Thompson PA, O’Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612–3621.
   PubMed Web of Science ®Google Scholar
• Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.
   PubMed Web of Science ®Google Scholar
• Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538–551.
   PubMed Web of Science ®Google Scholar
• Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997;89(6):2015–2023.
   PubMed Web of Science ®Google Scholar
• Lens D, Matutes E, Catovsky D, et al. Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia. 2000;14(3):427–430.
   PubMed Web of Science ®Google Scholar
• Flatley E, Chen AI, Zhao X, et al. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. Am J Clin Pathol. 2014;142(3):347–354.
   PubMed Web of Science ®Google Scholar
• Put N, Van Roosbroeck K, Konings P, et al. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol. 2012;91(6):863–873.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–641.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. Diagnosis of “double hit” diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematol Am Soc Hematol Educ Program. 2014;2014(1):90–99.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–2430.
   PubMed Web of Science ®Google Scholar
• Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia. 2009;23(2):225–234.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187–1198.
   PubMed Web of Science ®Google Scholar
• Ferreiro JF, Morscio J, Dierickx D, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica. 2015;100(7):e275–279.
   PubMed Web of Science ®Google Scholar
• Tirado CA, Chen W, García R, et al. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature. J Hematol Oncol J Hematol Oncol. 2012;5:54.
   PubMed Web of Science ®Google Scholar
• Young RM, Shaffer AL, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77–85.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–4843.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2008;349–358. doi:10.1182/asheducation-2008.1.349
   PubMedGoogle Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277.
   PubMed Web of Science ®Google Scholar
• Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183–3190.
   PubMed Web of Science ®Google Scholar
• Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770–1777.
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–2263.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–735.
   PubMed Web of Science ®Google Scholar
• Fromm JR, Kussick SJ, Wood BL. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol. 2006;126(5):764–780.
   PubMed Web of Science ®Google Scholar
• Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125(7):1061–1072.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Stul M, De Wolf-Peeters C, et al. Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin’s lymphoma. Haematologica. 2004;89(8):965–972.
   PubMed Web of Science ®Google Scholar